Indian pharmaceutical major Lupin has received approval from the United States Food and Drug Administration (USFDA) to market its generic version of Risperidone injection, a treatment used for schizophrenia and bipolar disorder. The authorization allows Lupin to introduce the therapy in the U.S. market, where the drug is expected to see strong demand given rising cases of psychiatric disorders.